Nucleic acid therapeutics and vaccines have the potential to revolutionize treatments and preventions for various diseases. Traditional forms of delivery often have limited effectiveness due to their inability to survive the harsh environment of the GI tract. Oral administration is particularly challenging, with nucleic acid payloads often failing to reach target cells or achieving insufficient transfection. Current solutions frequently entail invasive injections that can result in patient discomfort, risk of infections, and non-compliance. Furthermore, they often suffer from issues relating to dosage control and the effective release of the therapeutic agent at the targeted site. There is a pressing need for effective and non-invasive methods of delivery that can ensure accurate targeting and high transfection efficiency.

Technology Overview:

Northeastern researchers have invented this technology that revolves around the NiMOS (Nanoparticles-in-Microsphere Oral System) for gene delivery and transfection in specific regions of the gastrointestinal (GI) tract (Figure 1). The system comprises biocompatible and biodegradable polymers. The NiMOS system is purposed to protect nucleic acid payloads from the harsh environment of the GI tract, ensuring efficient and effective delivery and transfection of targeted cells. The invention is uniquely differentiated due to its advanced NiMOS system offering an enhanced and specialized process for oral administration of nucleic acid therapeutics and vaccines. By safeguarding the nucleic acid payload in the adverse conditions of the GI tract, it allows for maximum efficiency in delivery and transfection. With the potential to treat and prevent various diseases as well as providing both mucosal and systemic immunity through DNA vaccines, this innovative technology holds a distinctive position in the medical field.


  • Effective delivery of nucleic acid therapeutics to specific regions of the GI tract
  • Protection of nucleic acid payloads from harsh GI environment
  • Potential for non-invasive oral delivery, improving patient comfort and compliance
  • Possibility of treating and preventing a broad range of diseases
  • May enable mucosal and systemic immunity via DNA vaccines


  • Treatment of genetic diseases by delivering targeted gene therapies orally
  • Vaccination delivery, potentially enhancing patient compliance due to non-invasive oral administration
  • Treatment of gastrointestinal diseases by specific targeting of affected areas
  • Cancer treatment through gene therapies or DNA vaccines delivered directly to the tumor site
  • Research tool for studying gene function and regulation in a controlled manner


Seeking industry partner/funding

Patent Information:
For Information, Contact:
Vaibhav Saini
Senior Manager Commercialization
Northeastern University
Mansoor Amiji